Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic associated with substantial …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 160
million infections and more than 3 million deaths worldwide. Although effective vaccines are …

In humans, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is highly
infective, often causes severe acute and/or long-term illness, and elicits a high rate of …

We retrospectively compared the long-term evolution of IgG anti-spike (S) and anti-
nucleocapsid (N) levels (Abbott immunoassays) in 116 non-severe and 115 severe SARS …

Understanding the trajectory, duration, and determinants of antibody responses after SARS-
CoV-2 infection can inform subsequent protection and risk of reinfection, however large …

Background The aim was to evaluate the necessity of coronavirus disease 2019 (COVID-19)
vaccination in persons with prior COVID-19. Methods Employees of the Cleveland Clinic …

Background The duration of humoral and T and B cell response after the infection of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unclear. Methods We …

Objective: We aimed to determine antibody (Ab) titres 3 months after the second dose of the
BNT162b2 coronavirus disease-2019 (COVID-19) vaccine and to explore clinical variables …

Major advances have been made in understanding the dynamics of humoral immunity
briefly after the acute coronavirus disease 2019 (COVID-19). However, knowledge …

Despite over 140 million SARS‐CoV‐2 infections worldwide since the beginning of the
pandemic, relatively few confirmed cases of SARS‐CoV‐2 reinfection have been reported …